Cambridge COVID-19 Trials

Researchers in Cambridge are working closely with global partner organisations to advance our understanding of coronavirus SARS-CoV-2. Our aim is to identify effective preventive and curative treatments for COVID-19 for the benefit of populations worldwide.

Current Studies

TACTIC

TACTIC-R

TACTIC-E

PROTECT-V

Our Researchers & Investigators

Dr Davinder Dosanjh

PROTECT-V (Sotrovimab) Co-Chief Investigator

Prof David Jayne

TACTIC-R Co-Lead

Dr Frances Hall

TACTIC-R Chief Investigator

Dr James Galloway

TACTIC-E Co-Lead

Dr Joseph Cheriyan

TACTIC-E Chief Investigator

Dr Rona Smith

PROTECT-V Chief Investigator

Prof Ian Wilkinson

Director, Cambridge Clinical Trials Unit

Dr Simon Bond

TACTIC Trials Statistician

View all

Prev Next

News & Media Updates

Cambridge drug trial rolled out across the UK to help protect kidney patients from coronavirus

Covid-19 treatment trial for kidney patients goes national

TACTIC-R update June 2021

The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government

Trials to find preventative COVID-19 treatments for most vulnerable to launch in UK

Preventative coronavirus treatments led by Cambridge University

A basket trial of prophylactic interventions in multiple at-risk patient groups

Can a tapeworm drug protect high risk kidney patients from Covid-19?

UNION’s nasal spray for COVID-19 enters a 1,500 high-risk patient study

Cambridge University Hospitals NHS Foundation Trust is leading a major new trial to discover whether a drug used to treat tapeworms can prevent high risk kidney patients getting Covid-19.

View all

Prev Next

Partners

Prev Next